Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin-Reference-Cited by-同舟云学术

Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin

Published:2017-01-04 Issue:2 Volume:60 Page:767-786
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Jones Peter¹²³^ORCID,Storer R. Ian¹²³,Sabnis Yogesh A.¹²³,Wakenhut Florian M.¹²³,Whitlock Gavin A.¹²³,England Katherine S.¹²³,Mukaiyama Takasuke¹²³,Dehnhardt Christoph M.¹²³,Coe Jotham W.¹²³,Kortum Steve W.¹²³,Chrencik Jill E.¹²³,Brown David G.¹²³,Jones Rhys M.¹²³,Murphy John R.¹²³,Yeoh Thean¹²³,Morgan Paul¹²³,Kilty Iain¹²³

Affiliation:

1. Medicine Design, ‡Pharmacokinetics, Dynamics and Metabolism, and §Inflammation and Immunology Research Unit, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139, United States

2. Medicine Design, and ⊥Medicinal Sciences, Pfizer Inc., 445 Eastern Point Road, Groton, Connecticut 06340, United States

3. Worldwide Medicinal Chemistry, ∇Structural Biology and Biophysics, and ○Pharmaceutical Sciences, Pfizer Ltd., Ramsgate Road, Sandwich, CT13 9NJ, U.K.

Funder

Pfizer

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.6b01634

Reference49 articles.

1. Janus kinase inhibitors in autoimmune diseases

2. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

3. Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection